BOT has announced that its Atopic Dermatitis (AD) Phase 2 clinical study did not reach its primary or secondary endpoints. We downgrade our SPEC BUY recommendation to a HOLD with a reduced-price target of $0.06 (from $0.29). To access the full report please log in under the Client Area at the bottom of this page.Read more
Argonaut | The Natural Choice in Resources.
© 2024 Argonaut.